Veracyte Inc (VCYT) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $40.07 (-1.23%), Market cap $3.33B, P/E ratio 38.60, 52-week low–high $23.03 ~ $49.38.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Financial statements, price targets, institutional (13F) holdings and related news for Veracyte Inc are updated in real time on BlackAll Trade.
Veracyte Inc trades at $40.07 (-1.23%). Real-time quotes and charts are available on BlackAll Trade.
Veracyte Inc has a market cap of about $3.33B. Its P/E ratio is 38.60.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Geno